July 16, 2019
FDA fast tracks review of Novartis’ sickle cell disease tested drug
Novartis said Tuesday that the USFDA marked its investigational sickle cell drug crizanlizumab for Priority Review, which could be the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.
